U.S. markets open in 8 minutes
  • S&P Futures

    4,246.25
    -0.25 (-0.01%)
     
  • Dow Futures

    34,251.00
    -37.00 (-0.11%)
     
  • Nasdaq Futures

    14,051.25
    +21.00 (+0.15%)
     
  • Russell 2000 Futures

    2,308.70
    -7.00 (-0.30%)
     
  • Crude Oil

    72.12
    0.00 (0.00%)
     
  • Gold

    1,859.30
    +2.90 (+0.16%)
     
  • Silver

    27.91
    +0.21 (+0.77%)
     
  • EUR/USD

    1.2115
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.4870
    -0.0120 (-0.80%)
     
  • Vix

    16.79
    +0.40 (+2.44%)
     
  • GBP/USD

    1.4109
    +0.0026 (+0.19%)
     
  • USD/JPY

    109.8980
    -0.1360 (-0.12%)
     
  • BTC-USD

    39,092.79
    -1,196.52 (-2.97%)
     
  • CMC Crypto 200

    969.04
    -41.57 (-4.11%)
     
  • FTSE 100

    7,179.23
    +6.75 (+0.09%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Medigus Announces Six Months Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·14 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

OMER, Israel, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Medigus Ltd. (“Medigus” or the “Company”) (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today its financial results for the first half-year period ended June 30, 2020.

The Company reported IFRS loss of $3.6 million and non-IFRS net loss of $3 million for the six months ended June 30, 2020.

Recent Highlights:

  • On February 18, 2020, the Company purchased 2,284,865 shares of Matomy Media Group Ltd. (LSE: MTMY, TASE: MTMY.TA) (“Matomy”) representing 2.32% of its issued and outstanding share capital. On March 24, 2020, the Company completed an additional purchase of 22,326,246 shares of Matomy, raising the Company aggregate holdings in Matomy to 24.99% of Matomy’s issued and outstanding share capital.

  • On March 6, 2020, the Company announced that ScoutCam, Inc. (OTC: SCTC) (“ScoutCam”), the Company’s majority owned subsidiary, closed an investment round in which ScoutCam raised $948,400.

  • On May 19, 2020, the Company announced that ScoutCam entered into and consummated a securities purchase agreement with M. Arkin (1999) Ltd. in connection with an investment of $2 million.

  • On May 19, 2020, the Company entered into an underwriting agreement with ThinkEquity, a division of Fordham Financial Management (the “Underwriter”), pursuant to which the Company agreed to sell to the Underwriter in a firm commitment public offering: (i) 575,001 ADSs for a public offering price of $1.50 per ADS, and (ii) 2,758,333 pre-funded warrants to purchase one ADS at a public offering price of $1.499, with an exercise price of $0.001. The immediate proceeds, gross and net of issuance expenses, from such securities issuance aggregated to approximately $5 million and $4.4 million, respectively.

  • On June 23, 2020, the Company entered into and consummated a Side Letter Agreement with ScoutCam, whereby the parties agreed to convert, at a conversion price of $0.484, an outstanding line of credit previously extended by the Company to ScoutCam, which as of the date of conversion amounted to $381,136, into (i) 787,471 shares of ScoutCam’s common stock, par value $0.001 per share, or the Common Stock, (ii) warrants to purchase 393,736 shares of Common Stock with an exercise price of $0.595, and (iii) warrants to purchase 787,471 shares of Common Stock with an exercise price of $0.893.

  • On July 15, 2020, the Company entered into a reseller agreement with Polyrizon Ltd. (“Polyrizon”), a private company engaged in developing biological gels for the purpose of protecting patients against biological threats, and preventing intrusion of allergens and viruses through the upper airways and eye cavities. As part of the reseller agreement the Company received an exclusive global license to resell the Polyrizon products, focusing on a unique Biogel for the protection from COVID-19 virus. The term of the license will be for four years, commencing upon receipt of sufficient FDA approvals for the lawful marketing and sale of the products globally. The Company shall have the right to purchase the Polyrizon products on a cost plus 15% basis for the purpose of reselling the products worldwide. In consideration for the license, Polyrizon shall be entitled to receive annual royalty payments equal to 10% of the Company’s annualized operating profit arising from the sale of the products.

  • In addition, On July 15, 2020, the Company and Polyrizon signed an ordinary share purchase agreement. The agreement includes investment of $10,000 and a loan of $94,000 that will be extended to Polyrizon. Pursuant to the investment, the Company was issued shares representing 19.9% of the issued and outstanding share capital of Polyrizon, on a fully diluted basis excluding outstanding deferred shares. In addition, the Company was granted the option, exercisable at the Company’s sole discretion, to invest an additional investment amount of $1,000,000, in consideration for shares of Polyrizon such that following the additional investment, the Company will own 51% of Polyrizon on a fully diluted basis excluding outstanding deferred shares. The option is exercisable until the earlier of April 23, 2023 or the consummation by Polyrizon of equity financing of at least $500,000 based on a pre-money valuation of at least $10,000,000.

Six months Financial Results:

  • Revenues for the six months ended June 30, 2020 were $73,000, a decrease of 49% compared to the six months ended June 30, 2019.

  • Research and development expenses for the six months ended June 30, 2020 were $356,000, a decrease of 24% compared to the six months ended June 30, 2019. The decrease was primarily due to the Company’s decision to cease the MUSE™ operation.

  • Sales and marketing expenses for the six months ended June 30, 2020 were $213,000, a decrease of 8% compared to the six months ended June 30, 2019.

  • General and administrative expenses for the six months ended June 30, 2020 were $2,639,000, an increase of 126% compared to the six months ended June 30, 2019. The increase was primarily due to an increase in payroll expenses, as a result of an increase in share based compensation, the hiring of additional employees and an increase in professional services. The increase in professional services are a result of the reorganization, following which ScoutCam began to operate as an independent company and business unit.

  • IFRS loss for the six months ended June 30, 2020 was $3,599,000, compared to IFRS loss of $1,804,000 for the six months ended June 30, 2019. The increase is attributed mainly to an increase in general and administrative expenses as described above, net loss in fair value of financial assets at fair value through profit or loss, share of net loss of associate accounted for using the equity method and a listing expense partially offset by an increase in income from changes in fair value of warrants issued to investors.

  • Non-IFRS loss for the six months ended June 30, 2020 was $2,962,000, compared to Non-IFRS loss of $1,645,000 for the six months ended June 30, 2019. The increase is attributed mainly to an increase in general and administrative expenses as described above, net loss in fair value of financial assets at fair value through profit or loss and share of net loss of associate accounted for using the equity method.

  • Non-IFRS results exclude the effect of stock-based compensation expenses, revaluation of warrants at fair value and listing expenses.

Six months ended

June 30,

(thousands of U.S. dollars)

2020

2019

IFRS Results

Loss for the year

$

(3,599

)

$

(1,804

)

Non-IFRS Results

Loss for the year

$

(2,962

)

$

(1,645

)

Balance Sheet Highlights:

  • Cash and cash equivalents totaled $10.2 million as of June 30, 2020, compared to $7 million on December 31, 2019.

  • Investment in Gix Internet (formerly known as Algomizer) Group totaled $4.3 million as of June 30, 2020, compared to $4.8 million. The decrease is attributed primarily to the decrease in fair value of Linkury’s shares.

  • Investment in Matomy totaled $1.1 million as of June 30, 2020.

  • IFRS equity totaled $13.4 million as of June 30, 2020, compared to $8.1 million as of December 31, 2019.

  • Non-IFRS equity totaled $13.2 million as of June 30, 2020, compared to $18.1 million as of December 31, 2019.

A reconciliation between IFRS equity results and non-IFRS equity results is provided following the financial statements that are part of this release. Non-IFRS results exclude revaluation of warrants at fair value, amortization of excess purchase price of associate and listing expenses.

Use of Non-IFRS Financial Results

In addition to disclosing financial results calculated in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board, this press release contains non-IFRS financial measures of net loss for the periods presented that exclude the effect of share-based compensation expenses, amortization of excess purchase price of associate and listing expenses. The Company’s management believes the non-IFRS financial information provided in this release is useful to investors’ understanding and assessment of the Company’s ongoing operations. Management also uses both IFRS and non-IFRS information in evaluating and operating its business internally, and as such deemed it important to provide this information to investors. The non-IFRS financial measures disclosed by the Company should not be considered in isolation, or as a substitute for, or superior to, financial measures calculated in accordance with IFRS, and the financial results calculated in accordance with IFRS and reconciliations to those financial statements should be carefully evaluated. Investors are encouraged to review the reconciliations of these non-IFRS measures to their most directly comparable IFRS financial measures provided in the financial statement tables herein.

About Medigus
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the Company’s advanced technology, please visit www.medigus.com.

Cautionary Note Regarding Forward Looking Statements

This press release may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of the Company’s management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Other risk factors affecting the Company are discussed in detail in the Company’s filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the Company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.

Contact (for media only)

Tatiana Yosef
Chief Financial Officer
+972-8-6466-880
ir@medigus.com

MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

June 30,

December 31,

2020

2019

Unaudited

Audited

USD in thousands

Assets

CURRENT ASSETS:

Cash and cash equivalents

10,172

7,036

Accounts receivables - trade

26

22

Inventory

1,239

900

Other current assets

616

321

12,053

8,279

NON-CURRENT ASSETS:

Property and equipment, net

332

137

Right-of-use assets, net

135

153

Investments accounted for using the equity method

2,069

1,149

Financial assets at fair value through profit or loss

3,309

3,616

5,845

5,055

TOTAL ASSETS

17,898

13,334


MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

June 30,

December 31,

2020

2019

Unaudited

Audited

USD in thousands

Liabilities and equity

CURRENT LIABILITIES:

Accounts payables – trade

311

75

Lease liabilities

85

119

Warrants at fair value

588

1,459

Contract liability

2,472

502

Accrued compensation expenses

497

607

Other current liabilities

450

603

4,403

3,365

NON-CURRENT LIABILITIES:

Lease liabilities

53

33

Contract liability

-

1,800

Retirement benefit obligation, net

5

5

58

1,838

TOTAL LIABILITIES

4,461

5,203

SHAREHOLDERS’ EQUITY:

Share capital – ordinary shares of NIS 1.00 par value: authorized – June 30, 2020 and December 31,2019 – 250,000,000 shares; issued and outstanding - June 30, 2020 – 128,818,758 shares December 31, 2019 – 82,598,738 shares

36,014

22,802

Share premium

38,210

47,873

Other capital reserves

13,430

12,492

Warrants

1,802

197

Accumulated deficit

(79,210

)

(76,657

)

Equity attributable to owners of Medigus Ltd.

10,246

6,707

Non-controlling interests

3,191

1,424

TOTAL SHAREHOLDERS’ EQUITY

13,437

8,131

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

17,898

13,334


MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS

Six months ended

Year ended

June 30,

December 31,

2020

2019

2019

Unaudited

Audited

USD in thousands

Revenues:

Products

69

59

188

Services

4

85

85

73

144

273

Cost of revenues:

Products

276

157

370

Services

-

85

85

276

242

455

Gross Loss

(203

)

(98

)

(182

)

Research and development expenses

(356

)

(471

)

(609

)

Sales and marketing expenses

(213

)

(232

)

(326

)

General and administrative expenses

(2,639

)

(1,168

)

(3,081

)

Net change in fair value of financial assets at fair value through profit or loss

(323

)

-

92

Share of net loss of associate accounted for using the equity method

(138

)

-

(216

)

Amortization of excess purchase price of associate

(546

)

-

-

Listing expenses

-

-

(10,098

)

Operating loss

(4,418

)

(1,969

)

(14,420

)

Changes in fair value of warrants issued to investors

789

7

142

Financial income in respect of deposits, bank commissions and exchange differences, net

30

154

99

Financial income, net

819

161

241

Loss before taxes on income

(3,599

)

(1,808

)

(14,179

)

Taxes benefit (Taxes on income)

-

4

1

Total comprehensive loss for the period

(3,599

)

(1,804

)

(14,178

)


MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six months ended

June 30,

2020

2019

Unaudited

USD in thousands

CASH FLOWS FROM OPERATING ACTIVITIES:

Cash flows used in operations (see Appendix)

(2,907

)

(2,013

)

Interest received

13

56

Interest paid

(8

)

-

Income tax paid

-

(3

)

Net cash flow used in operating activities

(2,902

)

(1,960

)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment

(233

)

(1

)

Payments for acquisitions of associate and financial assets at fair value through profit or loss

(1,616

)

-

Net cash flow generated from (used in) investing activities

(1,849

)

(1

)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of shares and warrants, net of issuance costs of Subsidiary

2,858

-

Principal elements of lease liability

(60

)

-

Proceeds from issuance of shares and warrants and from exercise of warrants, net of issuance costs

5,044

-

Net cash flow generated from financing activities

7,842

-

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

3,091

(1,961

)

BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD

7,036

10,625

GAIN FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

45

123

BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD

10,172

8,787


MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Appendix to the condensed consolidated statements of cash flows:

Six months ended

June 30,

2020

2019

Unaudited

USD in thousands

Net cash used in operations:

Loss for the period before taxes on income

(3,599

)

(1,808

)

Adjustment in respect of:

Retirement benefit obligation, net

-

(74

)

Gain from exchange differences on cash and cash equivalents

(45

)

(123

)

Depreciation and amortization

102

11

Interest received

(13

)

(56

)

Interest expenses

8

-

Profit on change in the fair value of warrants issued to investors

(789

)

(7

)

Stock-based compensation in connection with options granted to employees and service providers

880

166

Net change in the fair value of financial assets at fair value through profit or loss

323

-

Share of losses of associate company

138

-

Amortization of excess purchase price of associate

546

-

Changes in operating asset and liability items:

Increase in accounts receivable - trade

(4

)

(4

)

Decrease (increase) in other current assets

(295

)

39

Increase (decrease) in accounts payables - trade and customer advance payment

236

(161

)

Decrease in accrued compensation expenses

(110

)

(181

)

Increase in contract liabilities

170

583

Decrease in other current liabilities

(153

)

(90

)

Increase in inventory

(302

)

(308

)

Net cash used in operations

(2,907

)

(2,013

)


MEDIGUS LTD.

SUPPLEMENTAL RECONCILIATION OF IFRS TO NON-IFRS EQUITY

U.S. dollars in thousands

As of

As of

As of

June 30,

June 30,

December 31,

2020

2019

2019

IFRS equity

13,437

6,441

8,131

Revaluation of warrants at fair value

(789

)

(7

)

(142

)

Amortization of excess purchase price of associate

546

-

-

Listing expenses

-

-

10,098

Non-IFRS equity

13,194

6,434

18,087


MEDIGUS LTD.

SUPPLEMENTAL RECONCILIATION OF IFRS TO NON-IFRS RESULTS

U.S. dollars in thousands

Six months ended

June 30,

2020

2019

IFRS operating loss

(4,418

)

(1,969

)

Stock-based compensation

880

166

Amortization of excess purchase price of associate

546

-

Non-IFRS operating loss

(3,014

)

(1,803

)

IFRS Financing income, net

819

161

Revaluation of warrants at fair value

(789

)

(7

)

Non-IFRS Financing income (expenses), net

30

(154

)

IFRS loss for the year

(3,599

)

(1,804

)

Stock-based compensation expenses

880

166

Amortization of excess purchase price of associate

546

-

Revaluation of warrants at fair value

(789

)

(7

)

Non-IFRS net loss

(2,962

)

(1,645

)